Please enable Javascript
Samuel Cytryn, MD
Samuel Cytryn, MD, Memorial Sloan Kettering Cancer Center
Articles by Samuel Cytryn, MD
Investigating Novel Immunotherapy Combinations for Advanced Gastric and Esophageal Cancers
Samuel Cytryn, MD
Gastric Cancer
|
February 8, 2025
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
View More
Challenges, Prognosis, and Future Directions for Peritoneal Gastric Cancer
Yelena Janjigian, MD
Gastric Cancer
|
February 4, 2025
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
View More
Antibody Drug Conjugates for Gastric and Esophageal Cancers: Expert Insights
Yelena Janjigian, MD
Gastric Cancer
|
February 4, 2025
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
View More
The Role of ctDNA, Claudin 18.2, and PD-L1 in Patient-Centered Gastric Cancer Care
Yelena Janjigian, MD
Gastric Cancer
|
February 4, 2025
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
View More
Advancing Gastric and Esophageal Cancer Treatment With Biomarker-Driven Strategies
Yelena Janjigian, MD
Gastric Cancer
|
February 4, 2025
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
View More
FDA Approval of Tislelizumab: RATIONALE-305 Findings and Implications for Practice
Samuel Cytryn, MD
Gastric Cancer
|
January 24, 2025
Dr. Cytryn reviews the FDA approval of tislelizumab and shares thoughts on its clinical impact.
View More
Impact of Zolbetuximab on Gastric Cancer Treatment
Samuel Cytryn, MD
Gastric Cancer
|
January 24, 2025
Dr. Cytryn provides insights on the FDA approval of zolbetuximab and how it will impact clinical practice.
View More